Cargando…
Failure in post-transcriptional processing is a possible inactivation mechanism of AP-2 α in cutaneous melanoma
The loss of transcription factor AP-2α expression has been shown to associate with tumourigenicity of melanoma cell lines and poor prognosis in primary cutaneous melanoma. Altogether these findings suggest that the gene encoding AP-2α (TFAP2A) acts as a tumour suppressor in melanoma. To learn more o...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363258/ https://www.ncbi.nlm.nih.gov/pubmed/10864211 http://dx.doi.org/10.1054/bjoc.2000.1145 |
_version_ | 1782153658870267904 |
---|---|
author | Karjalainen, J M Kellokoski, J K Mannermaa, A J Kujala, H E Moisio, K I Mitchell, P J Eskelinen, M J Alhava, E M Kosma, V M |
author_facet | Karjalainen, J M Kellokoski, J K Mannermaa, A J Kujala, H E Moisio, K I Mitchell, P J Eskelinen, M J Alhava, E M Kosma, V M |
author_sort | Karjalainen, J M |
collection | PubMed |
description | The loss of transcription factor AP-2α expression has been shown to associate with tumourigenicity of melanoma cell lines and poor prognosis in primary cutaneous melanoma. Altogether these findings suggest that the gene encoding AP-2α (TFAP2A) acts as a tumour suppressor in melanoma. To learn more of AP-2α’s down-regulation mechanisms, we compared the immunohistochemical AP-2α protein expression patterns with the corresponding mRNA expression detected by in situ hybridization in 52 primary melanomas. Of the 25 samples with AP-2α protein negative areas, 16 (64%) expressed mRNA throughout the consecutive section. Nine specimens (36%) contained equally mRNA- and protein-negative areas, suggesting that the loss of AP-2α protein associated with lack of the mRNA transcript. The highly AP-2α protein-positive tumours (n = 27) were concordantly mRNA positive in 25 (92.6%) cases. Thirteen primary tumours were further analysed using microsatellite markers D6S470 and D6S263 for loss of heterozygosity (LOH) of a locus harbouring TFAP2A. LOHs or chromosome 6 monosomy were found in four out of five (80%) informative AP-2α mRNA- and protein-negative tumour areas, but also within five out of 13 (38%) informative AP-2α mRNA-positive tumour areas. This chromosome region is thus suggestive of harbouring a putative tumour suppressor gene of cutaneous melanoma, but this referring specifically to TFAP2A could not be completely verified in this analysis. We conclude that a failure in post-transcriptional processing of AP-2α is a possible inactivation mechanism of AP-2α in cutaneous melanoma. Copyright 2000 Cancer Research Campaign© 2000 Cancer Research Campaign |
format | Text |
id | pubmed-2363258 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2000 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23632582009-09-10 Failure in post-transcriptional processing is a possible inactivation mechanism of AP-2 α in cutaneous melanoma Karjalainen, J M Kellokoski, J K Mannermaa, A J Kujala, H E Moisio, K I Mitchell, P J Eskelinen, M J Alhava, E M Kosma, V M Br J Cancer Regular Article The loss of transcription factor AP-2α expression has been shown to associate with tumourigenicity of melanoma cell lines and poor prognosis in primary cutaneous melanoma. Altogether these findings suggest that the gene encoding AP-2α (TFAP2A) acts as a tumour suppressor in melanoma. To learn more of AP-2α’s down-regulation mechanisms, we compared the immunohistochemical AP-2α protein expression patterns with the corresponding mRNA expression detected by in situ hybridization in 52 primary melanomas. Of the 25 samples with AP-2α protein negative areas, 16 (64%) expressed mRNA throughout the consecutive section. Nine specimens (36%) contained equally mRNA- and protein-negative areas, suggesting that the loss of AP-2α protein associated with lack of the mRNA transcript. The highly AP-2α protein-positive tumours (n = 27) were concordantly mRNA positive in 25 (92.6%) cases. Thirteen primary tumours were further analysed using microsatellite markers D6S470 and D6S263 for loss of heterozygosity (LOH) of a locus harbouring TFAP2A. LOHs or chromosome 6 monosomy were found in four out of five (80%) informative AP-2α mRNA- and protein-negative tumour areas, but also within five out of 13 (38%) informative AP-2α mRNA-positive tumour areas. This chromosome region is thus suggestive of harbouring a putative tumour suppressor gene of cutaneous melanoma, but this referring specifically to TFAP2A could not be completely verified in this analysis. We conclude that a failure in post-transcriptional processing of AP-2α is a possible inactivation mechanism of AP-2α in cutaneous melanoma. Copyright 2000 Cancer Research Campaign© 2000 Cancer Research Campaign Nature Publishing Group 2000-06 2000-05-18 /pmc/articles/PMC2363258/ /pubmed/10864211 http://dx.doi.org/10.1054/bjoc.2000.1145 Text en Copyright © 2000 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Regular Article Karjalainen, J M Kellokoski, J K Mannermaa, A J Kujala, H E Moisio, K I Mitchell, P J Eskelinen, M J Alhava, E M Kosma, V M Failure in post-transcriptional processing is a possible inactivation mechanism of AP-2 α in cutaneous melanoma |
title | Failure in post-transcriptional processing is a possible inactivation mechanism of AP-2 α in cutaneous melanoma |
title_full | Failure in post-transcriptional processing is a possible inactivation mechanism of AP-2 α in cutaneous melanoma |
title_fullStr | Failure in post-transcriptional processing is a possible inactivation mechanism of AP-2 α in cutaneous melanoma |
title_full_unstemmed | Failure in post-transcriptional processing is a possible inactivation mechanism of AP-2 α in cutaneous melanoma |
title_short | Failure in post-transcriptional processing is a possible inactivation mechanism of AP-2 α in cutaneous melanoma |
title_sort | failure in post-transcriptional processing is a possible inactivation mechanism of ap-2 α in cutaneous melanoma |
topic | Regular Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363258/ https://www.ncbi.nlm.nih.gov/pubmed/10864211 http://dx.doi.org/10.1054/bjoc.2000.1145 |
work_keys_str_mv | AT karjalainenjm failureinposttranscriptionalprocessingisapossibleinactivationmechanismofap2aincutaneousmelanoma AT kellokoskijk failureinposttranscriptionalprocessingisapossibleinactivationmechanismofap2aincutaneousmelanoma AT mannermaaaj failureinposttranscriptionalprocessingisapossibleinactivationmechanismofap2aincutaneousmelanoma AT kujalahe failureinposttranscriptionalprocessingisapossibleinactivationmechanismofap2aincutaneousmelanoma AT moisioki failureinposttranscriptionalprocessingisapossibleinactivationmechanismofap2aincutaneousmelanoma AT mitchellpj failureinposttranscriptionalprocessingisapossibleinactivationmechanismofap2aincutaneousmelanoma AT eskelinenmj failureinposttranscriptionalprocessingisapossibleinactivationmechanismofap2aincutaneousmelanoma AT alhavaem failureinposttranscriptionalprocessingisapossibleinactivationmechanismofap2aincutaneousmelanoma AT kosmavm failureinposttranscriptionalprocessingisapossibleinactivationmechanismofap2aincutaneousmelanoma |